Amneal Boosts Guidance After Strong Q2, Biosimilar Deal Looms — Amneal Pharmaceuticals, Inc.

Event summary

Q2 2026 revenue up 10% YoY to $796M, driven by specialty and affordable medicines growth.
Net income surged 157% YoY to $58M, with adjusted EBITDA up 12% to $206M.
Raised full-year guidance for revenue ($3.1B-$3.2B) and adjusted EBITDA ($750M-$780M).
Debt repricing in July reduces interest costs by $12M annually, supporting leverage reduction goal.

The big picture

Amneal's strong Q2 performance reflects the resilience of its diversified portfolio, particularly in specialty and affordable medicines. The pending Kashiv Biosciences acquisition signals a strategic pivot toward biosimilars, a high-growth segment that could further differentiate Amneal from peers. With debt repricing reducing interest costs and guidance raised for the second time this year, the company appears well-positioned to navigate industry challenges while expanding its long-term growth opportunities.

What we're watching

Integration Risk: How Amneal will integrate Kashiv Biosciences to establish biosimilars as a durable growth vertical.
Debt Management: Whether the company can sustain its leverage reduction target below 3.0x by 2028 amid acquisition financing.
Market Positioning: The pace at which Amneal can diversify its portfolio to mitigate competition in generic and specialty segments.